Drugs / AMT-253 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05117138 | Jan 2022 → Dec 2023 | head and neck squamous cell carcinoma, melanoma, non-small cell lung carcinoma | Beijing Immunochina Medical Science & Technology Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMT-253 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05117138 ↗ |
| Modality | Cell therapy | “AMT-253 CAR-T cells” NCT05117138 ↗ |
| Route | Intravenous | “by intravenous drip” NCT05117138 ↗ |